Mark D. Tyson, II, MD, MPH

home / authors / mark-d-tyson-ii-md-mph

Mark D. Tyson II, MD, is a urologic oncologist with subspecialty interest in bladder cancer at Mayo Clinic in Phoenix, AZ.

Articles

Key Findings From BOND-003: Cretostimogene Grenadenorepvec in NMIBC

May 3rd 2024

Mark D. Tyson, II, MD, MPH, discusses the safety and efficacy findings from the BOND-003 trial of cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.

Background, Methods, and Design of BOND-003 in NMIBC

Mark D. Tyson, II, MD, MPH

May 3rd 2024

Mark D. Tyson, II, MD, MPH, discusses the background of the phase 3 BOND-003 study evaluating cretostimogene grenadenorepvec in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.

Experience With Cretostimogene Grenadenorepvec in NMIBC and Next Steps

Mark D. Tyson, II, MD, MPH

May 1st 2024

Mark D. Tyson, II, MD, MPH, concludes his conversation on the BOND-003 trial by discussing the next steps for research on cretostimogene grenadenorepvec.